Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Abstract Background Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate between Alzheimer’s disease and other neurodegenerative diseases. However, t...

Full description

Bibliographic Details
Main Authors: Nicolas R. Barthélemy, Randall J. Bateman, Christophe Hirtz, Philippe Marin, François Becher, Chihiro Sato, Audrey Gabelle, Sylvain Lehmann
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Tau proteins
Cerebrospinal fluid
Online Access:http://link.springer.com/article/10.1186/s13195-020-00596-4

Internet

http://link.springer.com/article/10.1186/s13195-020-00596-4

Similar Items